5270
Asmaa Badawy M. Darwish
Increasing the activity and safety of the anti-inflammatory drug lornoxicam via niosomal encapsulation
Niosomes, lornoxicam, inflammation
Increasing the activity and safety of the anti-inflammatory drug lornoxicam via niosomal encapsulation Niosomes are multilameller vesicular structure of nonionic surfactants, similar to liposomes and are composed of non-ionic surfactant instead of phospholipids which are the main components of liposomes. Niosomes or non-ionic surfactant vesicles are now widely studied as an alternative tool to liposomes. The research interest in niosomal formulations is recently widening because niosomes are able to overcome some disadvantages associated with liposomes, as surfactants are easily derivatized and give a higher versatility to the vesicular structure and moreover they have lower costs than phospholipids. Lornoxicam is one of the most effective non-steroidal antiinflammatorydrugs (NSAIDS). Lornoxicam is used mainly in the treatment of muscular, skeletal and joint disorders such as osteoarthritis and rheumatoid arthritis. The encapsulation of drug in niosomes would promote the drug’s efficacy, reduce the administered drug dose and decrease the toxic side effects via reducing the drug dose and dosing frequency, thus improving patient compliance.The purpose of this study was to develop lornoxicam niosomes aiming at increasing the efficacy of the medicament lornoxicam, prolonging its effect, and decreasing the drug toxicity by using less drug dose through niosomal encapsulation. The niosomes were prepared with different molar ratios using the vortex dispersion method. Charge inducing agents like dicetyl phosphate (-ve CIA) and stearylamine (+ve CIA) were added to the niosomal formulations to enhance the entrapment efficiencies of drug inniosomes. Drug niosomal entrapment efficiency was estimated and the results revealed that, at the same cholesterol content, neutral niosomes exhibited the highest drug entrapment efficiency (EE %) and the highest value was exhibited by the niosomal formulation F1 of the molar ratio Span 60/ CHOL with a mean EE% of (76.63%) , higher than all of the niosomal formulations investigated.
2016
Ph.d
Cairo
Pharmacy